Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences (ARTL) reported progress in its CAReS study for cancer anorexia, anticipating data by year-end. The company has over $10 million in cash as of May 31, 2021, enabling it to advance key milestones. Despite a net loss of $2.25 million for Q3 2021, up from $951,191 in Q3 2020, Artelo is focused on potential therapies that address significant unmet needs in cancer care. Recent highlights include positive early data for lead candidate ART27.13 and advancements in preclinical assets ART12.11 and ART26.12, targeting cancer treatment.
Artelo Biosciences (NASDAQ: ARTL), a clinical-stage biopharmaceutical company, will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 3:00 p.m. EST. During the virtual event, CEO Gregory D. Gorgas will discuss the company’s focus on therapeutics targeting lipid signaling pathways, particularly the endocannabinoid system. Artelo aims to address significant unmet medical needs across various conditions, including cancer and PTSD. Interested parties can access the presentation via a live webcast.
Artelo Biosciences (NASDAQ: ARTL) announced at the ICRS Symposium that Dr. Andrew Yates will present the ART27.13 Cancer Appetite Recovery Study poster on June 22. This study targets cancer anorexia, a condition affecting over 60% of late-stage cancer patients. Additionally, Prof. Saoirse O’Sullivan will present findings related to Artelo's ART12.11 CBD cocrystal on June 23, highlighting its potential in cancer care. Artelo aims to report initial results from the CAReS trial by Q4 2021, underscoring its focus on innovative therapies in oncology.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the LD Micro Invitational XI, scheduled for June 8-10, 2021. Gregory D. Gorgas, President and CEO, will host a virtual presentation on June 9 at 1:00 p.m. EST. Artelo focuses on developing therapeutics that impact the endocannabinoid system to address unmet medical needs in conditions like cancer and PTSD. For further details and registration, visit the LD Micro Invitational XI event page.
Kintara Therapeutics (Nasdaq: KTRA) announced the appointment of Tamara A. Seymour to its Board of Directors, replacing John Liatos, who remains as Senior VP of Business Development. Seymour, a seasoned finance executive with over 30 years in biotech, has successfully raised over $250 million in equity and debt financing. Under her leadership, Kintara progresses its cancer therapies, VAL-083 and REM-001, targeting glioblastoma and metastatic breast cancer, respectively. The Company aims to address significant unmet medical needs in oncology.
Artelo Biosciences has made significant strides in its clinical development, recently commencing patient enrollment in the Phase 1/2 CAReS study of ART27.13, aimed at treating cancer anorexia. The company reported positive pre-clinical results for its CBD cocrystal, ART12.11, showing enhanced efficacy in cancer models. Financially, Artelo holds approximately $11.2 million in cash and cash equivalents as of February 28, 2021, which provides ample runway for upcoming milestones. However, the net loss for the quarter was around $1.87 million, indicating ongoing financial challenges.
Artelo Biosciences (NASDAQ: ARTL) has announced the initiation of its Phase 1/2 Cancer Appetite Recovery Study (CAReS) for ART27.13, a therapeutic aimed at treating cancer-related anorexia affecting over 60% of late-stage cancer patients. The first patient has been dosed in Edinburgh, Scotland. The study aims to collect initial safety data by the end of 2021, assessing the drug's efficacy in increasing appetite and weight. ART27.13 targets a significant market devoid of approved therapies, with current global market valuation surpassing $2 billion.
Artelo Biosciences (NASDAQ: ARTL) has been accepted into the Alderley Park Oncology Development Program in the UK, which aims to support innovative oncology projects. This program, funded by Innovate UK and Cancer Research UK, could provide additional funding to Artelo's FABP5 inhibitor program, which has previously received nearly $8 million from the U.S. government. The program focuses on developing a pathway to validate FABP5 as a biomarker across multiple tumor types, suggesting broader applicability of ART26.12 in cancer therapy.
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that CEO Gregory Gorgas will present at the Q1 Virtual Investor Summit from March 23-25, 2021. The presentation is scheduled for March 23rd at 1:00 PM ET. This summit connects smallcap and microcap companies with qualified investors, featuring over 100 companies and 300 investors. Artelo focuses on developing therapeutics targeting lipid-signaling pathways, aiming to address significant health concerns such as cancer and pain. For more details, visit www.artelobio.com.
Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Tamara A. Seymour, CPA, to its board of directors. Ms. Seymour brings over 30 years of experience in corporate finance within the biotech sector, having successfully raised over $250 million in funding. Her background includes serving as CFO for various public and venture-backed companies, along with expertise in clinical development and commercialization. The board believes her insights will be crucial for Artelo's growth as it seeks to advance its therapeutic programs targeting lipid-signaling pathways.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
